Leber Congenital Amaurosis Clinical Trial
Official title:
A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study
Verified date | September 2023 |
Source | Spark Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is a follow-on to a Phase 1 dose-escalation and safety study.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | June 2030 |
Est. primary completion date | March 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years and older |
Eligibility | Inclusion Criteria: - Prior participation in Phase 1 study with unilateral, subretinal administration of AAV2-hRPE65v2. - Visual acuity equal to or greater than light perception. - Sufficient viable retinal cells in contralateral, previously uninjected eye, as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy. Must have either: 1) an area of retina within the posterior pole of > 100 µm shown on OCT; 2) = 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or 3) remaining visual field within 50 degrees of fixation. - Willingness to adhere to protocol and long-term follow-up as evidenced by written informed consent or parental permission and subject assent (where applicable). Exclusion Criteria: - Unable or unwilling to meet requirements of the study. - Participation in any other study of an investigational drug within the past six months. - Use of retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme; individuals who discontinue use of these compounds for 18 months may become eligible. - Prior intraocular surgery within six months. - Known sensitivity to medications planned for use in the peri-operative period. - Pre-existing eye conditions, such as glaucoma, or complicating systemic diseases that would preclude the planned surgery or could interfere with the interpretation of study. Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example: radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g. macular edema or proliferative changes). Also excluded would be subjects with immunodeficiency (acquired or congenital) as there could be susceptibility to opportunistic infection (such as CMV retinitis). - Individuals of childbearing potential who are pregnant or unwilling to use effective contraception for four months following vector administration. - Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study. - Subjects will NOT be excluded based on their gender, race, or ethnicity. |
Country | Name | City | State |
---|---|---|---|
United States | The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Spark Therapeutics |
United States,
Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM. AAV2 gene therapy readministration — View Citation
Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009 Nov 7;374(9701):1597-605. doi: 10.1016/S0140-6736(09)61836-5. Epub 2009 Oct 23. Erratum In: Lancet. 2010 Jan 2;375(9708):30. — View Citation
Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240-8. doi: 10.1056/NEJMoa0802315. Epub 2008 Apr 27. — View Citation
Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther. 2010 Mar;18(3):643-50. doi: 10.1038/mt.2009.277. Epub 2009 Dec 1. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events as a measure of safety and tolerability | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Visual acuity | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Visual field | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Pupillary light response | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Mobility testing | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Full-field light threshold sensitivity testing | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years | |
Secondary | Contrast sensitivity | The primary outcome measures are safety and tolerability. Secondary outcome measure(s) include changes in visual function as measured by subjective, psychophysical tests and by objective, physiologic tests. | 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01496040 -
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65
|
Phase 1/Phase 2 | |
Completed |
NCT02970266 -
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.
|
N/A | |
Completed |
NCT00516477 -
Safety Study in Subjects With Leber Congenital Amaurosis
|
Phase 1 | |
Active, not recruiting |
NCT03920007 -
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
|
Phase 1/Phase 2 | |
Recruiting |
NCT05906953 -
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00999609 -
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
|
Phase 3 | |
Terminated |
NCT03913130 -
Extension Study to Study PQ-110-001 (NCT03140969)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04855045 -
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.
|
Phase 2/Phase 3 | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Completed |
NCT00749957 -
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
Not yet recruiting |
NCT04731883 -
RPE65 Gene Therapy (LX101)for Leber's Congenital Amaurosis
|
N/A | |
Recruiting |
NCT05203939 -
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06064565 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial (LIGHT)
|
Early Phase 1 | |
Recruiting |
NCT06088992 -
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)
|
Early Phase 1 | |
Completed |
NCT00821340 -
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations
|
Phase 1 | |
Active, not recruiting |
NCT03913143 -
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
|
Phase 2/Phase 3 | |
Completed |
NCT02781480 -
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
|
Phase 1/Phase 2 | |
Completed |
NCT02714816 -
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65
|